Document:

Exhibit 10.3

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

Distribution and Supply Agreement

Amendment 1

 

Parnell Europe Pty Limited

 

AND

 

Eli Lilly and Company

 

    	 

    	 

    

  

This is Amendment number
1 to the agreement between Eli Lilly and Company and Parnell Europe Pty Ltd. titled Distribution and Supply Agreement and dated
February 9, 2011 (“Agreement”). By this amendment, entered into on this 2nd day of December,
2011, both parties agree as follows:

 

1.          Recitals

 

WHEREAS, Elanco and
Parnell are Parties to the Agreement in regard to the Zydax product;

 

WHEREAS, the Parties
agree to pursue revised Targeted Claims for Zydax as indicated in the revised Schedule 1, attached;

 

WHEREAS, Elanco agrees
to increase the amount of the EU Payment 1 and US Payment 1,

 

WHEREAS, Parnell agrees
to ***; and

 

NOW THEREFORE, the
Agreement is amended as follows:

 

2.          Amended
Provisions

 

a.           Schedule 1
is replaced with the revised Schedule 1 included below.

 

b.           In
section 1.0, a new definition New Trial Study is added as follows: “New Trial Study means a study with a mutually agreed
protocol that is reasonably designed to achieve and support a Zydax product in accordance with Schedule 1, as amended herein.”

 

c.           In
section 1.0, a new definition Zone is added as follows: “Zone means either the United States of America or the European
Economic Community”

 

d.           In
section 1.0, the definition of Zydax is amended to add, after the words “Schedule 4”, the phrase: “and
Schedule 1”

 

e.           In
section 2.3, the phrase “thirty (30) months” is replaced with “thirty eight (38) months.”

 

f.            In
Section 3.1(a)(i), the phrase “ and *** to be paid not later than January 10, 2012 after mutual execution of Amendment 1
to this Agreement.” is added at the end of the existing paragraph.

 

g.           In
Section 3.1(b)(i), the phrase “ and *** to be paid not later than January 10, 2012 after mutual execution of Amendment 1
to this Agreement.” is added at the end of the existing paragraph.

 

h.           A
new section is added as follows:

 

    	 

    	 

    

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

3.3           Parnell
agrees to *** in accordance with the mutually agreed protocol. ***may include ***.

 

i.            Section 13.1(a)
is replaced in its entirety as follows:

 

(a)          If
registration of Zydax has not occurred in a zone by the end of the 38th month after Commencement Date, Parnell will
pay monthly damages either in US dollars *** to Elanco beginning the first day of the first month after the 38th
month post Commencement Date. Damages will be the cash amount *** for the “US Delay Damages” and *** for the
“EU Delay Damages,” respectively.

 

j.            Section 13.1(b)
is replaced in its entirety as follows:

 

(b)          Payment
of the respective US Delay Damages or EU Delay Damages will continue until Zydax is registered in the Zone that was not
registered as of the 38th month post Commencement date, or until, in each case, the EU Delay Damages are equal
to $666,666 (Six Hundred and Sixty Six Thousand and Six Hundred and Sixty Six Hundred Dollars) and the US Delay Damages are
equal to $1,333,334 (One Million Three Hundred and Thirty Three Thousand and Three Hundred and Thirty Four Hundred Dollars). For
clarity delay damages are only payable in respect of the zone in which registration of the Product has not occurred as at the end
of the 38th month post Commencement Date.

 

k.          Section 13.1(d)
is replaced in its entirety as follows:

 

(d)          In
the event that Registration for Zydax has still not been granted in either Zone, or Parnell is unable to supply the minimum supply
quantities defined in Schedule 2 by the end of the ***month after the Commencement Date either party may terminate this Agreement
by giving the other notice in writing, such termination to take effect immediately.

 

l.            Section 13.2
is replaced in Its entirety as follows:

 

13.2         In
the event that Registration for Zydax has still not been granted in any Zone by the end of ***month after the Commencement Date,
either party may terminate this Agreement by giving the other notice in writing, such termination to take effect immediately.

 

m.           Section 33.10
is replaced in its entirety as follows:

 

33.10         Clauses 13,
16, 18, 19, 22 to 30, 32 and 33 will survive the expiration or earlier termination of this Agreement.

 

3.          Amendment
Terms

 

a.           The
provisions of this Amendment, to the extent they conflict with the Agreement shall supersede such conflicting provisions

 

    	2

    	 

    

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

b.           The
parties agree that the Agreement remains in full force and effect as amended

 

c.           The
amended provisions shall survive the termination of this amended Agreement to the extent necessary to serve the purpose intended.

 

    	3

    	 

    

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

 

IN WITNESS WHEREOF,
the parties have executed this Agreement Amendment 1, effective upon the last date entered below.

 

	ELI LILLY AND COMPANY	 
	 	 	 
	By	/s/ Jeff Simmons 	 
	 	 	 
	Title	President  	 
	 	 	 
	Date	2 December 2011	 
	 	 	 
	Parnell Europe Pty Ltd	 
	 	 	 
	By	/s/ Robert Joseph	 
	 	 	 
	Title	Chief Executive Officer	 
	 	 	 
	Date	2 December 2011 	 
	 	 	 
	Attachment:  Revised Schedule 1	 

 

    	 

    	 

    

 

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED
AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***,
HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

  

SCHEDULE 1

 

Products

 

	
        Product 
	 	Trade Name	 	Presentation	 	Active ingredient
	Zydax 100 Injection	 	Zydax	 	20mL preserved multiple dose vial	 	Glucuronoxylan Sulfate sodium ***

  

***

 

Currently the targeted
Label of Zydax will include, but not be limited to the following:

 

***

 

    	S-1 - 1Exhibit 10.6

  

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS
OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY
WITH THE SECURITIES AND EXCHANGE COMMISSION

  

Unit 4, Century Estate

476 Gardeners Road

Alexandria NSW 2015

 

PO Box 1035

Mascot

NSW 1460

 

Telephone: 61-2-9667 4411

Facsimile: 61-2-9667 4139

Website: www.parnell.com

Email: info@parnell.com

 

1 February 2011

 

Robert Joseph

 

Further to your continuing employment the
following constitutes the contract of employment (“the Contract”) between Parnell Corporate Services Pty Ltd,
Unit 4, Century Estate, 476 Gardeners Road Alexandria NSW 2015, (“the Company”), and you (“the Employee”).

 

		1.	Appointment

 

You are appointed to the offices of Director
and Chief Executive Officer for each of the companies listed in Schedule 1 to this Agreement.

 

You will work in any location as directed
by the Company.

 

		2.	Term of Appointment

 

		(a)	Upon acceptance of this offer by you, your employment will be deemed to have commenced on 21 August,
2006 (“the Position”) and continues until your employment is terminated.

 

		(b)	All service prior to the date of acceptance of this Contract will continue to be recognised for
the purpose of calculating any service-based entitlements including long service leave, annual leave, personal/carer’s leave
and parental leave.

 

		3.	General duties

 

During the Employment, you will be required
to:

 

		(a)	devote the whole of your time, attention and skill during normal business hours to perform the
duties;

 

		(b)	faithfully and diligently perform the duties and exercise the powers;

 

		(i)	consistent with the position of Chief Executive Officer or,

 

		(ii)	as otherwise assigned to you by the Board of Directors.

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

		(c)	promote the interests of the Company and any Group
Company; and

 

		(d)	obey all reasonable directions;

 

Subparagraphs (a) to (d) of this clause
together are the duties.

 

		4.	Duty to report

 

You must report directly to the Board of
Directors.

 

		5.	Hours

 

You will work 37.5 hours per week and such
reasonable additional hours as may be required to perform the duties.

 

In regard to these reasonable additional
hours, you and the Company together acknowledge the matters referred to in section 62 (3) of the Fair Work Act (“the
Act”) including your level of responsibility and the remuneration and related incentives you enjoy in the Position.

 

		6.	Base Salary

 

During the period that you serve the Company
under this agreement, the Company must pay you the Base Salary of *** per annum divided into twelve equal parts with one part paid
each month or as otherwise agreed between the parties.

 

		7.	Superannuation

 

The Company will make contributions to
a complying superannuation fund on your behalf in the amount of *** per annum.

 

		8.	Incentive Scheme

 

The Company may at its absolute discretion
vary, replace or rescind the scheme at any time and determine your participation or not in the scheme at any time. Presently, pursuant
to the scheme, you may be offered to subscribe for shares in the capital of the Company. The rights attaching to these shares are
set out in the constitution of the Company and will be exclusively administered according to the Parnell Executive Share Plan Rules.

 

		9.	Holding offices

 

		(a)	Without further remuneration, you agree to accept such offices in Parnell Group or related bodies
corporate of Parnell Group as from time to time may be reasonably required.

 

		(b)	On termination, or earlier at the Board’s request, you will resign from these positions and
complete all necessary documentation to give effect to the resignation.

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

		(c)	Parnell Group will hold an appropriate Directors and Officers Liability Insurance policy with a
reputable organisation in relation to your position as a Public Officer of Parnell Group.

 

		10.	Leave Entitlement

 

You;

 

		(a)	are entitled to public holidays, long service leave and annual leave in conformity with statutory
entitlements; and

 

		(b)	must take annual leave and long service leave at a period or periods agreed between the Company
and you and in the absence of agreement, when determined or directed by the Company.

 

		11.	Accrued leave

 

Subject to any statutory provision, the
Company may require you to take any significant accrued leave entitlement or may make a payment to your accrued leave pursuant
to Section 94 of the Act.

 

		12.	Personal / Carers Leave

 

You are entitled to *** Personal / Carers
Leave per annum. Personal / Carers Leave may be taken when the Employee;

 

		(a)	is sick; or

 

		(b)	is required to care for a member of their immediate family or household.

 

		13.	Charity Leave

 

The Company offers *** paid leave each year for you to perform
volunteer work for a charity deemed suitable by the Company.

 

		14.	Paid Maternity Leave

 

Unpaid Maternity Leave is prescribed in
the Act. The Company may provide, at its absolute discretion, an employee who has completed at least 12 months continuous service
prior to becoming pregnant and who is the primary carer for a child, with eight (8) weeks paid leave to commence on the birth or
adoption of a child, less any amount payable under any Federal Government Paid Parental Leave Scheme.

 

		15.	Medical Examination

 

You agree that that the Company may, at
its expense, require you to undergo a medical examination by a registered medical practitioner or practitioners nominated by the
Company (after the Company has considered your wishes in respect of the appointment of the registered medical practitioner) and
a copy of any medical report furnished by such medical practitioner shall be available to both parties. For the avoidance of doubt,
the Company may exercise this right for the purposes of:

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

		•	Determining whether granting you ongoing sick leave is appropriate;

		•	Determining whether your employment should be terminated for incapacity;

		•	Assessing your fitness for work and/or to return to work after a period of sick leave; or

		•	Obtaining a second opinion where you have provided a medical certificate/report.

 

		16.	Your obligations on Confidentiality

 

You must:

 

		(a)	keep any Information secret and confidential, except to the extent that you are required by law
to disclose the Information;

 

		(b)	take all reasonable and necessary precautions to maintain the secrecy and prevent the disclosure
of any Information; and

 

		(c)	not disclose Information to any third parties without first obtaining the written consent of the
Board except in the ordinary and proper course of employment with the Company.

 

		17.	Survival of obligations

 

Your obligations in clause 15 survive the
termination of your employment with the Company.

 

		18.	Exclusive engagement

 

While you are employed by the Company, you must not be engaged,
concerned or interested in any other business without the prior written consent of the Board or its nominee.

 

		19.	Termination

 

		19.1	Other than in circumstances provided in 18.3 below, the Company may terminate the employment by
giving six (6) months written notice or at its election by making a payment in lieu of the notice period which will bring your
employment to an immediate end.

 

		19.2	Notice given by you shall be six (6) months from the end of the day upon which notice is
given.

 

		19.3	Notwithstanding any other clause in this contract the Company may terminate this agreement immediately
if you:

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

 

		(a)	commit any act which may detrimentally affects the Company or any Group Company, including but
not limited to an act of fraud, wilful disobedience, or misconduct;

 

		(b)	wilfully or persistently or materially breach this agreement; or

 

		(c)	become medically incapacitated or become liable to be dealt with under any law relating to mental
health.

 

		19.4	Obligations on termination

 

		(a)	On termination of this agreement, the you must return to the Company all tangible property of the
Company or any Group Company including, but not limited to, all books, documents, list of suppliers, list of customers, papers,
materials, phones, personal data appliances, credit cards, security passes, passwords for any systems or applications, cars and
keys held by you or under your control.

 

		(b)	You may not copy, transmit or download any file, email, document or any Information from the Company
network or Company computer to a personal computer, personal storage device or personal email account during or after your employment,
including during your notice period, without the Company’s consent.

 

		(c)	You agree to the Company deducting any over-payments, outstanding debts or money owed to it by
you from your statutory entitlements.

 

		20.	Post Employment Restraints

 

During your Employment with the Company
you will acquire or become familiar with Confidential Information, Trade Secrets, customer connections and information, supplier
connections and information and business connections and information which are valuable to the Company and which you acknowledge
you cannot and will not use during or after your employment for your own or the benefit of a third party without the Company’s
consent. The limitations and acknowledgment are intended by the parties to protect the Company’s interests.

 

		20.1	Restricted areas and restricted activities

 

You must not, without the prior written
consent of the Company do any of the following during the employment of within *** of the Termination Date:

 

		(a)	directly or indirectly carry on (whether alone, as an employee, in partnership or in joint venture
with anyone else) or otherwise be concerned with or interested in (whether as trustee, principal, agent, shareholder, unit holder
or in any other capacity) any business similar to or competitive with the business of the Company, or any joint venture (whether
corporate or unincorporated) in which any Group Company has an interest exceeding 10% and whose principal business is similar to
that of the Company in Australia.

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

		(b)	at any time induce or attempt to induce any director, manager or employee of the Company to terminate
his/her employment with the Company, whether or not that person would commit a breach of that person’s contract of employment;

 

		(c)	at any time employ any person who has been a director, manager, employee, supplier, services provider
or consultant to the Company during your employment who is or may be likely to be in possession of any confidential information
or trade secrets relating to the business of;

 

		(i)	the Company; or

 

		(ii)	suppliers or services provider used or retained by the Company;

 

		(d)	solicit or persuade any person whom you have dealt with while employed by the Company or any person
who is in the process of negotiating with the Company at the Termination Date in relation to any business carried on by the Company,
to cease doing business with the Company or reduce the amount of business which the person would normally do with the Company.

 

		20.2	Restraint reasonable

 

		(a)	You and the Company consider the restraints contained in this clause to be reasonable and intend
the restraints to operate to the maximum extent.

 

		(b)	If these restraints:

 

		(i)	are void as unreasonable or invalid; and

 

		(ii)	would be reasonable or valid if part of the wording were deleted or the period or areas were reduced,
the restraints will apply with the modifications necessary to make them effective.

 

		20.3	Restraints independent

 

The restraints contained in this clause
are separate, distinct and several, so that the unenforceability of any restraint does not affect the enforceability of the other
restraints.

 

		20.4	Your Acknowledgement 

 

You acknowledge that:

 

		(a)	you have and will obtain Information concerning the business and finances of the Company and Group
Companies including trade secrets and industrial processes;

 

		(b)	disclosure of Information could materially harm the Company;

 

		(c)	the restrictive covenants contained in this clause are reasonable and necessary for the protection
of the Information and goodwill of the Company;

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

		(d)	the remedy of damages may be inadequate to protect the interest of the Company and the Company
is entitled to seek and obtain injunctive relief, or any other remedy, in any Court; and

 

		(e)	in view of the importance of the restraints contained in this part for the protection of the proprietary
interests of the Company, this part will survive the termination of your employment with the Company in all circumstances including
repudiation by the Company of the remainder of this contract.

 

		21.	Business Expenses and Equipment

 

		(a)	Parnell will reimburse you for all expenses incurred in the course of your employment including
all costs of local and international travel and entertainment costs incurred having regard to the nature of travel and entertainment
relative to your position as Chief Executive Officer.

 

		(b)	For the purposes of performing your duties, Parnell will provide you with access to any facilities
and equipment generally required to fulfil your position as Chief Executive Officer including but not limited to Blackberry®
and associated equipment, laptop computer, remote internet access, eTag and other travel accessories and equipment commensurate
with the nature of travel that you undertake as Chief Executive Officer.

 

		22.	Governing law and jurisdiction

 

		(a)	This contract is governed by the laws of New South Wales.

 

		(b)	The parties irrevocably submit to the exclusive jurisdiction of the courts of New South Wales.

 

		(c)	Each of the parties irrevocably waives any objection to the venue of any legal process on the basis
that the process has been brought in an inconvenient forum.

 

		23.	Entire Contract

 

This contract constitutes the entire agreement
between the parties in respect of the matters dealt with in this contract and supersedes all prior contracts, agreements, understandings,
arrangements and negotiations in respect of your employment with the Company.

 

		24.	Definitions In this contract:

 

“Board” means the Board
of the Parnell Pharmaceuticals Holdings Pty Ltd established pursuant to the constitution of the Company.

 

“Group” means Parnell
Pharmaceuticals Holdings Pty Ltd and all of its subsidiaries;

 

“Group Company” means
a ‘related body corporate’, and any ‘Associated entity’ of the Company as those expressions are defined
in the Corporations Law;

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

“Information” means:

 

any information in respect of the Company’s
business including customer information, sales and marketing tactics and strategies which are not in the public domain; and any
document, book, account, process, patent, specification, drawing, design or know-how which;

 

		(a)	comes to the notice of you in the course of your employment; or

 

		(b)	is generated by you in the course of performing your obligations.

 

“The Act” means the
Fair Work Act (2009) (Cth).

 

“Termination Date” means the date when you
cease to be employed by the Company.

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

 

EXECUTED by the parties as an agreement:

 

SIGNED

for Parnell Corporate Services Pty Ltd

by its representative

in the presence of

 

 

	/s/ Erika Kristy Vikor	 	/s/ Alan R. Bell
	Witness	 	Representative
	 	 	 
	Erika Kristy Vikor	 	Alan R. Bell
	Name (please print)	 	Name (please print)
	 	 	 
	SIGNED	 	 
	by Robert Joseph	 	 
	in the presence of:	 	 
	 	 	 
	/s/ Erika Kristy Vikor	 	/s/ Robert Joseph
	Witness	 	Robert Joseph
	 	 	 
	Erika Kristy Vikor	 	 
	Name (please print)	 	 

 

    	 

    	CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT.  EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH AN ASTERISK ***, HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION

    

  

SCHEDULE 1

 

COMPANIES TO WHICH ROBERT JOSEPH WILL
BE APPOINTED

DIRECTOR AND CHIEF EXECUTIVE OFFICER

 

Parnell Pharmaceuticals Holdings Pty Ltd

 

Parnell Pharmaceuticals Pty Ltd

 

Parnell Technologies Pty Ltd

 

Parnell Technologies NZ Pty Ltd

 

Parnell Corporate Services Pty Ltd

 

Parnell Australia Pty Ltd

 

Parnell New Zealand Ltd (a New Zealand company)

 

Parnell Manufacturing Pty Ltd

 

Australian Pharma Services Pty Ltd

 

Parnell North America Pty Ltd

 

Parnell Europe Pty Ltd

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]